MassMEDIC lobbies for CDRH funding
This article was originally published in The Gray Sheet
Executive Summary
A March 20 letter to Massachusetts' congressional delegation from the device trade group urges members to work with House Appropriations/Agriculture Subcommittee Ranking Democrat Marcy Kaptur (Ohio) to ensure CDRH receives the additional $22 mil. (plus inflation) in FY 2004 approps needed to keep MDUFMA implementation on track. "This approach ensures that user-fee funds do not displace congressional appropriations, and allows CDRH to upgrade information technology and other infrastructure necessary to carry out a user-fee program and meet the performance goals," MassMEDIC President Tom Sommer writes. CDRH Director David Feigal has indicated the center may use industry fees to compensate for budget shortfalls (1"The Gray Sheet" March 17, 2003, p. 3). The device center must receive $45 mil. (plus inflation) by FY 2005 or the program sunsets...
You may also be interested in...
User Fee Funds Will Not Be Confined To Premarket Review Activities – Feigal
Device user fees will be allocated toward activities other than premarket review as CDRH struggles to compensate for fiscal 2003 appropriation shortfalls
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.